ABT-737 can overcome BCL2 and BCL-XL and is currently in phase 1 clinical trial in small cell lung cancer (SCLC) and chronic lymphocytic leukaemia [45, 70]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.